InventisBio has initiated a Phase III clinical trial for its novel TYK2 allosteric inhibitor nomelcitinib (D-2570) in moderate-to-severe plaque psoriasis. The multicentre, randomised, double-blind, placebo-controlled study (n=390) will evaluate efficacy and safety, with the primary endpoint being the percentage of patients achieving ≥90% improvement in Psoriasis Area and Severity Index (PASI 90) at week 16. Nomelcitinib selectively targets TYK2’s JH2 domain, inhibiting cytokine signalling and inflammation.

In Phase II trials, nomelcitinib performed favourable: 75% to 77.5% of patients achieved PASI 90 at 12 weeks (vs 5% placebo), rivalling biologic drugs. Globally, 23 TYK2 inhibitors are in development, including 12 allosteric types. Nomelcitinib joins five others in Phase III, positioning InventisBio to compete with leaders like BMS's deucravacitinib (the only approved TYK2 inhibitor), Takeda's zasocitinib and Hansoh Pharma's HS-10374.